A Study of Mitapivat in Participants With Sickle Cell Disease and Nephropathy

Sponsor
Agios Pharmaceuticals, Inc.
Study ID
NCT06286046
Phase
PHASE2
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
16 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The primary purpose of this study is to evaluate the effect of mitapivat on albumin creatinine ratio (ACR) response in participants with sickle cell disease (SCD) and nephropathy.

Key Dates

Start date
Mar 31, 2026
Status verified
Mar 2026
Primary completion
May 31, 2027
Completion
Dec 31, 2028

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Mitapivat 100 mg
    Participants will receive mitapivat 100 milligrams (mg) tablet, orally, twice daily (BID) for up to 24 months.

Primary Outcome Measure

Percentage of Participants With Albumin Creatinine Ratio (ACR) Response [ Time Frame: Baseline up to 6 months ]

Related Studies